Welcome to our dedicated page for CapsoVision SEC filings (Ticker: CV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc. reporting person Rebecca Ann Petersen acquired 24,834 shares of common stock and holds stock options adjusted for a recent reverse split. The Form 4 shows a purchase of 24,834 shares at $0.3663 per share on 08/18/2025, resulting in 24,834 shares beneficially owned directly. The filing also reports two option grants (7,507 and 17,327 underlying shares) with an exercise price of $0.3663, exercisable through 10/31/2031 and 03/22/2032; the options’ share counts and exercise price reflect a 1-for-3.33 reverse stock split tied to the issuer’s IPO. One option is fully vested and the other is partially vested. The Form 4 was filed late due to an administrative error.
CapsoVision reported a transformative quarter highlighted by a completed IPO and continued operational challenges. The company completed an initial public offering in July 2025, selling 5,629,978 shares at $5.00 per share for gross proceeds of approximately $28.1 million and net proceeds of about $23.4 million. As of June 30, 2025, the company had approximately $1.1 million in cash and an accumulated deficit of $140.4 million. The financials for the six months ended June 30, 2025 show an operating loss of $10,033, a net loss of $10,000, and net cash used in operating activities of $9,512. Management disclosed substantial doubt about going concern.
The company executed a 1-for-3.33 reverse stock split effective July 2, 2025, converted outstanding preferred stock into common stock prior to the IPO, and increased authorized common shares to 300 million. Regulatory and product updates include a 510(k) filing for CapsoCam Colon in Q2 2025 targeting FDA clearance in early 2026 and a development agreement with Canon for CMOS sensors with up to $4.1 million in fees. Material weaknesses in internal controls were identified with remediation in progress.
CapsoVision, Inc. filed a current report to note that it issued a press release on August 14, 2025 announcing its financial results for the fiscal quarter ended June 30, 2025. The company is using this filing to formally furnish that earnings press release as Exhibit 99.1.
The earnings information in the press release is furnished rather than filed, which means it is not automatically incorporated into other securities law filings unless specifically referenced later. The report also identifies the company’s common stock as trading on The Nasdaq Stock Market LLC under the symbol CV.